11632 RESULTS
COMMENT Weight loss is common among persons with dementia and Alzheimer disease (AD). Nevertheless, it has remained unclear why and when AD patients lose weight. Some recent studies have suggested that weight loss may start already during the preclinical phase of
COMMENT Observations reported from the Honolulu-Asia Aging Study (HAAS) illustrate the relationship between dementia and weight history, change in weight and body mass index (BMI), and how dementia risk factors are related to weight changes. In general, the HAAS
COMMENT Clincial evidence suggests that long- term use of statins is associated with a decreased risk of Alzheimer disease (AD). As these drugs block the synthesis of cholesterol, much research has been focused on the importance of cholesterol metabolism in the p
COMMENT Rifampicin has real potential in treating Parkinson's patients. I believe failure to follow up on this lead would do a grave disservice to all those now sufferiing with PD. 0 jcrobertson
COMMENT Both Cell papers extend the cascades up- and downstream of GSK-3β considerably by providing molecular links from growth-factor signalling and cell adhesion to microtubule dynamics and axon organization—all most essential processes in evolution in "th
COMMENT Time for the ubiquitin-proteasome system Most likely, dysfunction of the ubiquitin-proteasome system (UPS) contributes to the neuropathogenesis of various types of conformational diseases (for example, Alzheimer, Parkinson, and Huntington diseases). The p
COMMENT Pedrini et al. identified two connected pathways with ROCK1 as the central player. Their findings indicate that ROCK1 inhibits α-secretase activity; two different statins inhibit ROCK1 via reducing isoprenylation of the Rho GTPases. Thus, statins could ac
COMMENT This manuscript confirms and extends a previous study showing that statin treatment can increase the release of sAPPα [1]. The biochemical mechanism by which HMG-CoA reductase inhibition leads to this increase isn’t fully understood. The authors present i
COMMENT In this study, John Trojanowski suggests drugs such as paclitaxel may be a useful therapy for AD. The Kikuno group mentions the recent findings that paclitaxel induces thymidine phosphorylase in solid tumours (1). A study by Yoshinaga et al suggests that
COMMENT As Sam Gandy says regarding his research on statin effects in Alzheimer disease: "If it seems like a mess, it is." Hippocrates said, "Every disease has a nature of its own, and each arises from its own natural cause." Why, 2,000 years
COMMENT polyglutamine aggregation at very high concentrations. Unfortunately, the authors did not comment on whether or
COMMENT in this comment fits in logical succession with the body of work on gene dosage. It revisits the
COMMENT Trainees wanting a succinct overview of the MAP2/Tau family of microtubular-associated proteins should start here. They should be aware, however, to expect larger numbers of interacting partners than the list in Table 2. Pathophysiology is not within the
COMMENT The findings in the paper by Zhao and colleagues are intriguing: The presence of a 46-residue form of Aβ inside the cell, but not secreted, raises the question of whether this longer, presumably more amyloidogenic Aβ might serve as a nidus for intracellul
COMMENT I think this will be a well-cited paper; the authors have performed a large amount of work, 18F-dopa PET scanning of 13 apparently asymptomatic carriers of single heterozygous parkin mutations. This is not the first paper to tackle this subject but it is
